Skip to main content
Contact us

Intermediates CDMO Companies
Intermediates Contract Manufacturing Services

Your Trusted Intermediates CDMO Partners for Pharmaceutical Contract Manufacturing

Showing 45 facilities
CARBOGEN AMCIS | Bubendorf
Switzerland

CARBOGEN AMCIS | Bubendorf

CARBOGEN AMCIS

Desarrollo y fabricación cGMP de API de gran potencia, incluidos conjugados anticuerpo-fármaco (ADC)

MARKETS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

BATCH SIZE: Small, Medium

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (V09-10) Radiopharmaceuticals, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (B) Blood and blood forming organs

COMPLIANCE: EMA (EU GMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), World Health Organization (GMP / HACCP), FDA (cGMP), ISO

CATEGORY / PRODUCT: SERVICES, BIOLOGICS, CHEMICAL-SYNTHETIC

REGION: Europe

USE: Human, Veterinary

SERVICES: Analytical / QC services, Manufacturing services, Regulatory services, Development services, Quality Assurance services

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

CARBOGEN AMCIS | Vionnaz
Switzerland

CARBOGEN AMCIS | Vionnaz

CARBOGEN AMCIS

Desarrollo de principios activos muy potentes y producción a peque a escala según las normas cGMP, incluidas la cromatografía y la liofilización

BATCH SIZE: Small

COMPLIANCE: EMA (EU GMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), World Health Organization (GMP / HACCP), FDA (cGMP), ISO

CATEGORY / PRODUCT: SERVICES, CHEMICAL-SYNTHETIC

REGION: Europe

MARKETS: ANVISA (Brazil), PMDA (Japan), FDA (USA), CDSCO (India), EMA (EU), MFDS (South Korea), TGA (Australia), NMPA (China), Health Canada (Canada), MHRA (UK)

USE: Human, Veterinary

SERVICES: Analytical / QC services, Manufacturing services, Development services, Quality Assurance services

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

Hikal Ltd | Bangalore, India
India

Hikal Ltd | Bangalore, India

Hikal Ltd.

Desarrollo de procesos cGMP, escalado y fabricación de APIs de moléculas pequeñas, nuevas entidades moleculares (NMEs) e intermedios, desde gramos hasta kilogra

MARKETS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), CDSCO (India), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

BATCH SIZE: Small, Medium, Large

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (C) Cardiovascular system, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (V06) Nutrients

COMPLIANCE: EMA (EU GMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), TGA (Australia GMP), FDA (cGMP), ECOVADIS, ISO, Halal Research Council, COFEPRIS

CATEGORY / PRODUCT: COSMETICS, SERVICES, NUTRACEUTICALS, CHEMICAL-SYNTHETIC

USE: Human, Veterinary

REGION: APAC

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

SERVICES: Manufacturing services, Regulatory services, Development services

CARBOGEN AMCIS | Shanghai, China
China

CARBOGEN AMCIS | Shanghai, China

CARBOGEN AMCIS

Fabricación a gran escala.

MARKETS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

BATCH SIZE: Small, Medium, Large

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (B) Blood and blood forming organs, (V06) Nutrients

CATEGORY / PRODUCT: SERVICES, OLIGONUCLEOTIDES, CHEMICAL-SYNTHETIC

USE: Human

COMPLIANCE: ANVISA (Brazil B-GMP), NMPA (China GMP)

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services

REGION: APAC

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

Sichuan Huiyu Pharmaceuticals Co., Ltd. - R&D Site
China

Sichuan Huiyu Pharmaceuticals Co., Ltd. - R&D Site

Seacross Pharmaceutical Co Ltd

The R&D Center plays a fundamental role in supporting the development of both APIs and finished dosage forms.

MARKETS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

BATCH SIZE: Small, Medium, Large

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (V09-10) Radiopharmaceuticals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (G) Genito urinary system and sex hormones, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (B) Blood and blood forming organs, (V06) Nutrients

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS, OLIGONUCLEOTIDES, PARTICLE ENGINEERING, CHEMICAL-SYNTHETIC

COMPLIANCE: ISP (Chile BPM), Roszdravnadzor (Russia GMP), ANMAT (Argentina nueva GMP), EMA (EU GMP), PMDA/MHLW (Japan GMP), IFS, DIGEMID, UAE Ministry of Health & Prevention, ANVISA (Brazil B-GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), French Service-Public (CIR), TGA (Australia GMP), FDA (cGMP), NSF, NMPA (China GMP), SFDA (Saudi Food & Drug Authority), BRCGS, ECOVADIS, ISO, Halal Research Council, INVIMA, Health Canada (Canada GMP), SQF (Safe Quality Food), TITCK (Turkish Health Authorities), MSPAS, MFDS/KFDA (Republic of Korea GMP), COFEPRIS

CONTROLLED SUBSTANCES: Lowest potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse

BSL (Biological Safety Level): 3, 4, 1, 2

USE: Human

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services

REGION: APAC

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

CARBOGEN AMCIS | Veenendaal
Netherlands

CARBOGEN AMCIS | Veenendaal

CARBOGEN AMCIS

Fabricación a gran escala de colesterol, vitamina D y análogos.

MARKETS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

BATCH SIZE: Small

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (V09-10) Radiopharmaceuticals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (G) Genito urinary system and sex hormones, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (B) Blood and blood forming organs, (V06) Nutrients

COMPLIANCE: ISP (Chile BPM), Roszdravnadzor (Russia GMP), ANMAT (Argentina nueva GMP), EMA (EU GMP), PMDA/MHLW (Japan GMP), IFS, DIGEMID, UAE Ministry of Health & Prevention, ANVISA (Brazil B-GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), French Service-Public (CIR), TGA (Australia GMP), FDA (cGMP), NSF, NMPA (China GMP), SFDA (Saudi Food & Drug Authority), BRCGS, ECOVADIS, ISO, Halal Research Council, INVIMA, Health Canada (Canada GMP), SQF (Safe Quality Food), TITCK (Turkish Health Authorities), MSPAS, MFDS/KFDA (Republic of Korea GMP), COFEPRIS

CATEGORY / PRODUCT: COSMETICS, SERVICES, CHEMICAL-SYNTHETIC

REGION: Europe

USE: Human, Veterinary

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

BSL (Biological Safety Level): 1

CARBOGEN AMCIS | Manchester, UK
United Kingdom

CARBOGEN AMCIS | Manchester, UK

CARBOGEN AMCIS

Descubra nuestras capacidades de fabricación de ingredientes cosméticos, química fina y síntesis personalizada de productos farmacéuticos intermedios

BATCH SIZE: Small, Medium, Large

CATEGORY / PRODUCT: COSMETICS, SERVICES, OLIGONUCLEOTIDES, CHEMICAL-SYNTHETIC

REGION: Europe

USE: Human

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Development services

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day)

COMPLIANCE: ECOVADIS, ISO, Halal Research Council

THERAPEUTIC AREAS OF EXPERTISE (ATC): (D) Dermatologicals

MARKETS: MHRA (UK)

CARBOGEN AMCIS | Neuland
Switzerland

CARBOGEN AMCIS | Neuland

CARBOGEN AMCIS

Desarrollo y fabricación a mediana escala

MARKETS: Turkish Health Authorities, ANVISA (Brazil), PMDA (Japan), FDA (USA), CDSCO (India), EMA (EU), MFDS (South Korea), TGA (Australia), NMPA (China), Health Canada (Canada), MHRA (UK)

BATCH SIZE: Small, Medium

COMPLIANCE: PMDA/MHLW (Japan GMP), World Health Organization (GMP / HACCP), FDA (cGMP)

CATEGORY / PRODUCT: SERVICES, CHEMICAL-SYNTHETIC

REGION: Europe

USE: Human, Veterinary

SERVICES: Analytical / QC services, Manufacturing services, Regulatory services, Development services, Quality Assurance services

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

Sichuan Huiyu Pharmaceuticals Co., Ltd. - API Manufacturing Site
China

Sichuan Huiyu Pharmaceuticals Co., Ltd. - API Manufacturing Site

Seacross Pharmaceutical Co Ltd

As one of three core sites, alongside the R&D center and formulation plant, our API manufacturing facility plays a vital role in the integrated supply chain.

MARKETS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)

BATCH SIZE: Small, Medium, Large

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (V09-10) Radiopharmaceuticals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (G) Genito urinary system and sex hormones, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (B) Blood and blood forming organs, (V06) Nutrients

COMPLIANCE: ISP (Chile BPM), Roszdravnadzor (Russia GMP), ANMAT (Argentina nueva GMP), EMA (EU GMP), PMDA/MHLW (Japan GMP), IFS, DIGEMID, UAE Ministry of Health & Prevention, ANVISA (Brazil B-GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), French Service-Public (CIR), TGA (Australia GMP), FDA (cGMP), NSF, NMPA (China GMP), SFDA (Saudi Food & Drug Authority), BRCGS, ECOVADIS, ISO, Halal Research Council, INVIMA, Health Canada (Canada GMP), SQF (Safe Quality Food), TITCK (Turkish Health Authorities), MSPAS, MFDS/KFDA (Republic of Korea GMP), COFEPRIS

CONTROLLED SUBSTANCES: Lowest potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse

BSL (Biological Safety Level): 3, 4, 1, 2

USE: Human

SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services

REGION: APAC

CATEGORY / PRODUCT: OLIGONUCLEOTIDES, BIOLOGICS, CHEMICAL-SYNTHETIC

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

Pharmaron API Commercial Synthesis Coventry (US)
United States

Pharmaron API Commercial Synthesis Coventry (US)

Pharmaron

Instalación comercial de moléculas peque as (RSM/API)

BATCH SIZE: Small, Medium, Large

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (H) Systemic hormonal preparations excl. sex hormones and insulins, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (G) Genito urinary system and sex hormones, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (B) Blood and blood forming organs, (V06) Nutrients

CATEGORY / PRODUCT: SERVICES, CHEMICAL-SYNTHETIC

CONTROLLED SUBSTANCES: Lowest potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse

USE: Human, Veterinary

MARKETS: PMDA (Japan), FDA (USA), EMA (EU), MFDS (South Korea), TGA (Australia), NMPA (China), Health Canada (Canada), MHRA (UK)

SERVICES: Logistics, Manufacturing services, Development services

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

REGION: North America

COMPLIANCE: FDA (cGMP), ECOVADIS, ISO

Viswa Laboratories Pvt Ltd
Spain

Viswa Laboratories Pvt Ltd

Viswa Laboratories Private Limited

CRAMS/CDMO, API, Productos intermedios y especialidades químicas

BATCH SIZE: Small, Medium, Large

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (M) Musculoskeletal system, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (D) Dermatologicals

CATEGORY / PRODUCT: SERVICES, CHEMICAL-SYNTHETIC

REGION: Europe, APAC

MARKETS: ANVISA (Brazil), CDSCO (India), Russian Health Authorities, EMA (EU), NMPA (China)

USE: Human, Veterinary

COMPLIANCE: World Health Organization (GMP / HACCP)

SERVICES: Manufacturing services, Regulatory services, Development services

CONTROLLED SUBSTANCES: Lower potential for abuse

BSL (Biological Safety Level): 2

OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day)

Pharmaron API Commercial Synthesis Shaoxing (China)
China

Pharmaron API Commercial Synthesis Shaoxing (China)

Pharmaron

Instalación comercial de moléculas peque as (RSM/API) / péptidos

BATCH SIZE: Small, Medium, Large

THERAPEUTIC AREAS OF EXPERTISE (ATC): (R) Respiratory system, (V09-10) Radiopharmaceuticals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (V01) Allergens, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (V04) Diagnostic agents, (S) Sensory organs, (G) Genito urinary system and sex hormones, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (B) Blood and blood forming organs, (V06) Nutrients

USE: Human, Veterinary

SERVICES: Analytical / QC services, Manufacturing services, Regulatory services, Development services, Quality Assurance services

REGION: APAC

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 5,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 1 / low-hazard (PDE > 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day)

CATEGORY / PRODUCT: PARTICLE ENGINEERING, CHEMICAL-SYNTHETIC

MARKETS: FDA (USA), NMPA (China)

COMPLIANCE: FDA (cGMP), NMPA (China GMP), ISO

More facilities on the network

Register to unlock the full catalog with contact details and locations.

+27 more facilities

Create free account

Pharmaceutical intermediates, whether used in active pharmaceutical ingredient (API) synthesis or complex chemical processing, require controlled manufacturing conditions to ensure consistency, purity, and scalability. To meet regulatory and quality expectations, pharmaceutical and biotech companies rely on experienced intermediates CDMO companies to deliver precise and compliant production.

From process development to GMP-scale synthesis, partnering with a specialist in intermediates contract manufacturing ensures chemical accuracy, regulatory alignment, and supply reliability, key elements for successful drug development pathways.


How to Choose Intermediates CDMO Companies

When selecting intermediates CDMO companies, it is essential to consider partners with strong know-how in process optimization and scale-up. Key evaluation criteria include:

  • Process development expertise: Route synthesis optimization and impurity profiling.
  • GMP manufacturing capabilities: For intermediates, APIs, and advanced chemical steps.
  • Handling of complex reactions: High-pressure, cryogenic, hydrogenation, or hazardous chemistries.
  • Purification technologies: Chromatography, crystallization, distillation.
  • Analytical and QC support: Structure confirmation, residual solvents, and in-process testing.
  • Regulatory experience: For FDA, EMA, and global GMP certification.

A qualified intermediates CDMO delivers robustness, traceability, and efficiency across all manufacturing stages.


Key Services Offered by Intermediates Contract Manufacturers

Leading intermediates contract manufacturing providers typically offer:

  • Custom synthesis: Tailored manufacturing of intermediates for small to large-volume needs.
  • Process development and optimization: Reaction design, impurity control, and scalability.
  • GMP production: For clinical and commercial supply.
  • Tech transfer: From R&D to full-scale chemical plants.
  • Analytical development: Method validation, release testing, and stability programs.
  • Supply chain and logistics support: Secure shipment of regulated chemical substances.
  • Regulatory documentation: For Drug Master File (DMF), IMPD, and dossier submissions.

These services ensure quality, compliance, and sustainable sourcing throughout the project lifecycle.


Advantages of Partnering with Intermediates CDMO Companies

Collaborating with specialized intermediates CDMO companies offers several strategic benefits:

  • Deep chemical expertise: In advanced synthesis and scale-up.
  • Reduced development risk: Through proven industrial technologies.
  • Cost optimization: Via efficient process engineering and yield improvement.
  • Accelerated timelines: With integrated services from lab to manufacturing.
  • Regulatory readiness: Backed by strong GMP and compliance systems.

An expert intermediates CDMO enables smooth transition from early-stage chemistry to commercial production.


Intermediates CDMO Companies

Some of the most reputable intermediates CDMO companies include:

  • ChemCon Gmbh: Contract development and manufacturing partner for APIs and fine chemicals specialized in transferring R&D projects into fully cGMP-compliant manufacturing processes. [See CDMO profile]
  • Pharmaron: Commercial API Small Molecules /Peptides Synthesis. [See CDMO profile]
  • Laboratori Alchemia SRL: Our facilities are designed to satisfy production requirements ranging from laboratory scale for synthetically complex products. [See CDMO profile]
  • Viswa Laboratories Pvt Ltd: CRAMS/CDMO, APIs, Intermediates and specialty chemicals. [See CDMO profile]
  • Cambrex: Specialize in late-phase and commercial API development and cGMP manufacturing. [See CDMO profile]
  • Laboratori Alchemia SRL: Our facilities are designed to satisfy production requirements ranging from laboratory scale for synthetically complex products. [See CDMO profile]
  • Actylis Eugene: Chemical Process Discovery, Development, cGMP, and Commerical Manufacturing Services. [See CDMO profile]
  • CARBOGEN AMCIS: Development and cGMP manufacturing of Highly Potent API including Antibody Drug Conjugates (ADC). [See CDMO profile]
  • Sichuan Huiyu Pharmaceuticals: API manufacturing facility that plays a vital role in our integrated supply chain. [See CDMO profile]
  • MENADIONA: Contract development and manufacturing partner located in Spain for APIs. [See CDMO profile]
  • Apeloa Pharmaceutical: Apeloa CDMO provides world-class discovery, development, and manufacturing services for Active Pharmaceutical Ingredients (APIs), Intermediates, and Registered Starting Materials (RSMs). [See CDMO profile]
  • Hikal Ltd | Bangalore, India: cGMP process development, scale-up and manufacturing of small molecule APIs, NMEs and intermediates, from gram to kilogram and tonne scale, supporting projects from laboratory stage through commercial launch. [See CDMO profile]
  • Demo facility: Tissue therapy, Cell therapy and GTMP (Gene Therapy). [See CDMO profile]

Related Information


Let MAI CDMO Help You Find the Right Intermediates CDMO Partner

At MAI CDMO, we connect pharmaceutical and biotech companies with the most qualified intermediates CDMO companies for chemical synthesis, scale-up, and regulatory support. Whether you require custom manufacturing for a strategic intermediate or full GMP production, our network of intermediates contract manufacturing partners ensures precision, compliance, and timely delivery.

Looking for a trusted intermediates manufacturing partner? Contact us today to accelerate your development timeline.